Pharma R&D and clinical data
Pharmaceutical R&D depends on data that is highly valuable and highly regulated. It can only be sourced subject to legal, ethical and privacy requirements. This guide covers the landscape and the responsible path.
A cautious starting point
Clinical and patient data is special-category data and tightly governed. Everything here is subject to applicable legal, privacy, ethical and contractual requirements and to appropriate approvals. Anonymised, aggregated and synthetic data are the right defaults.
The pharma data landscape
- Clinical-trial data: under strict conditions and approvals.
- Real-world data: anonymised outcomes and usage.
- Market data: prescribing and pharmaceutical-market data.
- Synthetic: synthetic clinical data for development and testing.
Common use cases
Research and evidence generation, market access and commercial analytics, epidemiology, and software development using synthetic data.
Why synthetic and anonymised data lead
Because clinical data is so sensitive, synthetic and robustly anonymised data are often the only practical route for development and many analytics, letting work begin while approvals proceed.
Sourcing considerations
Legal basis, ethics approvals and contracts come first. Anonymisation of clinical data is hard and must be evidenced. Provenance and documentation are essential.
In a managed model
A managed partner can source anonymised, aggregated and synthetic pharma data responsibly, using secure environments and documenting approvals and provenance.
Governance precedes access
Clinical and patient data is special-category, so legal basis, ethics approval and contractual safeguards come first, and use is usually confined to secure environments. Anonymised, aggregated and synthetic data are the right defaults, and anonymising rich clinical data is genuinely hard, so it must be evidenced, not assumed.
Where value is found
Within those bounds, the data supports research and evidence, market access and commercial analytics, epidemiology, and synthetic-data-driven development. Provenance, approvals and documentation are essential throughout, and the European Health Data Space is shaping standardised secondary use.
- Clinical data is special-category: subject to legal, ethical and privacy requirements.
- Default to anonymised, aggregated or synthetic data.
- Anonymising clinical data is hard and must be evidenced.
- Use secure environments and document approvals and provenance.
Sources & further reading
- EMA: clinical and real-world data frameworks.
- European Health Data Space (EHDS) proposals.
- EUR-Lex: Regulation (EU) 2016/679 (GDPR), special categories.
- Clinical Trials Regulation (EU) No 536/2014.
We source anonymised, aggregated and synthetic pharma data responsibly. Get a no-obligation quote.